VAXCYTE INC (PCVX)
US92243G1085 - Common Stock
We assign a fundamental rating of 3 out of 10 to PCVX. PCVX was compared to 572 industry peers in the Biotechnology industry. PCVX has a great financial health rating, but its profitability evaluates not so good. PCVX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
PCVX had negative earnings in the past year.
In the past year PCVX has reported a negative cash flow from operations.
In the past 5 years PCVX always reported negative net income.
PCVX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -14.26%, PCVX belongs to the best of the industry, outperforming 83.72% of the companies in the same industry.
PCVX has a Return On Equity of -14.85%. This is amongst the best in the industry. PCVX outperforms 89.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.26% | ||
| ROE | -14.85% | ||
| ROIC | N/A |
ROA(3y)-27.21%
ROA(5y)-36.17%
ROE(3y)-30.37%
ROE(5y)-42.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PCVX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for PCVX has been increased compared to 1 year ago.
The number of shares outstanding for PCVX has been increased compared to 5 years ago.
PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 40.84 indicates that PCVX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 40.84, PCVX belongs to the top of the industry, outperforming 97.88% of the companies in the same industry.
PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 40.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
PCVX has a Current Ratio of 17.88. This indicates that PCVX is financially healthy and has no problem in meeting its short term obligations.
PCVX's Current ratio of 17.88 is amongst the best of the industry. PCVX outperforms 93.45% of its industry peers.
A Quick Ratio of 17.88 indicates that PCVX has no problem at all paying its short term obligations.
The Quick ratio of PCVX (17.88) is better than 93.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.88 | ||
| Quick Ratio | 17.88 |
3. Growth
3.1 Past
The earnings per share for PCVX have decreased strongly by -38.14% in the last year.
EPS 1Y (TTM)-38.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, PCVX will show a decrease in Earnings Per Share. The EPS will decrease by -2.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.43%
EPS Next 2Y-7.84%
EPS Next 3Y-8.42%
EPS Next 5Y-2.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PCVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PCVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PCVX's earnings are expected to decrease with -8.42% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.84%
EPS Next 3Y-8.42%
5. Dividend
5.1 Amount
No dividends for PCVX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VAXCYTE INC
NASDAQ:PCVX (1/14/2025, 8:00:01 PM)
After market: 78.1 -0.04 (-0.05%)78.14
-3.03 (-3.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.95%
Inst Owner Change0.02%
Ins Owners0.49%
Ins Owner Change-1.77%
Market Cap9.74B
Analysts87.06
Price Target152.89 (95.66%)
Short Float %11.86%
Short Ratio11.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.41%
Min EPS beat(2)-9.49%
Max EPS beat(2)28.3%
EPS beat(4)2
Avg EPS beat(4)-4.73%
Min EPS beat(4)-66.45%
Max EPS beat(4)28.7%
EPS beat(8)4
Avg EPS beat(8)-1.03%
EPS beat(12)5
Avg EPS beat(12)-2.79%
EPS beat(16)9
Avg EPS beat(16)1.97%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.23%
PT rev (3m)0.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.2%
EPS NY rev (1m)0%
EPS NY rev (3m)9.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.85 | ||
| P/tB | 2.85 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.6
EYN/A
EPS(NY)-4.8
Fwd EYN/A
FCF(TTM)-4.94
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS0
BVpS27.42
TBVpS27.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.26% | ||
| ROE | -14.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-27.21%
ROA(5y)-36.17%
ROE(3y)-30.37%
ROE(5y)-42.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2909.43% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.88 | ||
| Quick Ratio | 17.88 | ||
| Altman-Z | 40.84 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)913.97%
Cap/Depr(5y)584.35%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.79%
EPS Next Y-0.43%
EPS Next 2Y-7.84%
EPS Next 3Y-8.42%
EPS Next 5Y-2.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.55%
EBIT Next 3Y-26.5%
EBIT Next 5YN/A
FCF growth 1Y-279.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-200.4%
OCF growth 3YN/A
OCF growth 5YN/A